Table 4 Prognostic values of clinical variables for predicting progression-free survival and overall survival in 63 patients with metastatic renal cell carcinoma analyzed by using univariate and multivariate Cox proportional hazards regression models.

From: First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology

Risk factor

Risk category

Univariate

Multivariate

PFS

OS

PFS

OS

HR

p

HR

p

HR

95% CI

p

HR

95% CI

p

IMDC risk classification

Poor

4.53

0.033

14.28

 < 0.001

1.72

–

0.189

2.88

1.10–8.47

0.030

Nephrectomy

Not performed

1.51

0.219

6.22

0.013

   

0.24

–

0.622

Spindle histology

Positive

5.16

0.023

10.71

0.001

1.96

–

0.162

2.87

1.40–11.00

0.020

NLR

2.9 or more

3.51

0.061

8.72

0.003

   

1.83

–

0.176

CRP

0.5 or more

4.87

0.027

12.50

0.002

1.63

1.70–4.02

0.031

3.07

0.97–7.75

0.058

Metastatic organ

4 or more

5.22

0.022

7.30

0.007

2.21

–

0.137

1.20

–

0.274

  1. Statistically significant factors are shown in bold.
  2. PFS progression-free survival, OS overall survival, HR Hazard ratio, CI confidence interval, IMDC International metastatic renal cell carcinoma database consortium, NLR neutrophil lymphocyte ratio, CRP C reactive protein.
Back to article page